D. S. Korobko

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Vera Bril, Artur Drużdż, Julian Großkreutz et al. · The Lancet Neurology · 2023 · 227 citations

Clinical Trials, Generalised Myasthenia Gravis, Pharmacotherapy +3

Genome-wide significant association with seven novel multiple sclerosis risk loci

Christina M. Lill, Felix Luessi, Antonio Alcina et al. · Journal of Medical Genetics · 2015 · 41 citations · Full text

Association of SNPs of CD40 Gene with Multiple Sclerosis in Russians

E. А. Sokolova, N A Malkova, D. S. Korobko et al. · PLoS ONE · 2013 · 36 citations · Full text